| 59. APPsα Gene Therapy for Alzheimer's Disease R Fol, S Ludewig, T Abel, SW Weyer, JP Roederer, F Brod, M Audrain, ... Molecular Therapy 24, S26, 2016 | 1 | 2016 |
| AAV-CYP46A1 is beneficial in Alzheimer's disease: from mice to non-human primates S Alves, K Michaelsen-Preusse, M Audrain, R Aron-Badin, A Lamaziere, ... HUMAN GENE THERAPY 28 (12), A77-A77, 2017 | | 2017 |
| AAV-mediated CYP46A1 delivery is beneficial in Alzheimer's disease models: towards a clinical application S Alves, K Michaelsen-Preusse, M Audrain, R Aron-Badin, A Lamaziere, ... HUMAN GENE THERAPY 27 (11), A47-A47, 2016 | | 2016 |
| Adeno-associated virus-based gene therapy for CNS diseases M Hocquemiller, L Giersch, M Audrain, S Parker, N Cartier Human gene therapy 27 (7), 478-496, 2016 | 316 | 2016 |
| Alzheimer's disease animal model N Cartier-Lacave, J Braudeau, N Deglon, P Hantraye, M Audrain US Patent 10,159,227, 2018 | | 2018 |
| Alzheimer's disease animal model N Cartier-Lacave, J Braudeau, N Deglon, P Hantraye, M Audrain US Patent 10,986,821, 2021 | | 2021 |
| Alzheimer’s disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression M Audrain, R Fol, P Dutar, B Potier, JM Billard, J Flament, S Alves, ... Molecular neurodegeneration 11, 1-17, 2016 | 46 | 2016 |
| Cerebral phospho-tau acts synergistically with soluble Aβ42 leading to mild cognitive impairment in AAV-AD rats B Souchet, M Audrain, Y Gu, MF Lindberg, NS Orefice, E Rey, N Cartier, ... The Journal of Prevention of Alzheimer's Disease 9 (3), 480-490, 2022 | 7 | 2022 |
| Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology MA Burlot, J Braudeau, K Michaelsen-Preusse, B Potier, S Ayciriex, ... Human molecular genetics 24 (21), 5965-5976, 2015 | 126 | 2015 |
| Correction to: Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in cerebral Aβ amyloidosis mouse normalizes clinical phenotype and complement … JV Haure-Mirande, M Wang, M Audrain, T Fanutza, SH Kim, S Heja, ... Molecular Psychiatry, 2018 | | 2018 |
| Correction: Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in cerebral Aβ amyloidosis mouse normalizes clinical phenotype and complement subnetwork … JV Haure-Mirande, M Wang, M Audrain, T Fanutza, SH Kim, S Heja, ... Molecular Psychiatry 24 (3), 472, 2019 | 2 | 2019 |
| Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology JV Haure-Mirande, M Audrain, T Fanutza, SH Kim, WL Klein, C Glabe, ... Acta neuropathologica 134, 769-788, 2017 | 108 | 2017 |
| Dual-Specificity Protein Phosphatase 4 (DUSP4) Overexpression Improves Learning Behavior Selectively in Female 5xFAD Mice, and Reduces β-Amyloid Load in Males and Females AL Pan, M Audrain, E Sakakibara, R Joshi, X Zhu, Q Wang, M Wang, ... Cells 11 (23), 3880, 2022 | 5 | 2022 |
| Dual-specificity protein phosphatase 6 (DUSP6) overexpression reduces amyloid load and improves memory deficits in male 5xFAD mice AL Pan, M Audrain, E Sakakibara, R Joshi, X Zhu, Q Wang, M Wang, ... bioRxiv, 2023.08. 24.554335, 2023 | | 2023 |
| Effect of Aging and a Dual Orexin Receptor Antagonist on Sleep Architecture and Non-REM Oscillations Including an REM Behavior Disorder Phenotype in the PS19 Mouse Model of … K Kam, K Vetter, RA Tejiram, WD Pettibone, K Shim, M Audrain, L Yu, ... Journal of Neuroscience 43 (25), 4738-4749, 2023 | 7 | 2023 |
| Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats B Souchet, M Audrain, Y Gu, MF Lindberg, NS Orefice, E Rey, N Cartier, ... The Journal of Prevention of Alzheimer's Disease 10 (1), 150-150, 2023 | | 2023 |
| Evaluation of memantine in AAV-AD rat: a model of late-onset Alzheimer’s disease predementia B Souchet, M Audrain, S Alves, R Fol, S Tada, NS Orefice, B Potier, ... The Journal of prevention of Alzheimer's disease 9 (2), 338-347, 2022 | 5 | 2022 |
| Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD T Afroz, E Chevalier, M Audrain, C Dumayne, T Ziehm, R Moser, ... Neurobiology of Disease 179, 106050, 2023 | 11 | 2023 |
| Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework R Ollier, A Fuchs, F Gauye, K Piorkowska, S Menant, M Ratnam, ... MAbs 15 (1), 2232087, 2023 | 6 | 2023 |
| Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice B Souchet, M Audrain, JM Billard, J Dairou, R Fol, NS Orefice, S Tada, ... Acta neuropathologica communications 7, 1-15, 2019 | 40 | 2019 |
